An interventional study of Actimyo° and IMU in Multiple Sclerosis, sponsored by Laurent Servais. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-12.
Sponsored by Laurent Servais · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 157 studies in Multiple Sclerosis with a site in Belgium — 14 open to participants now, 30 under way, 10 of them phase 3. Multiple Sclerosis · Belgium.
Among the 157 studies in Multiple Sclerosis with a site in Belgium, this one is the 117th largest by enrollment of the 132 interventional ones that give a count, is one of 8 that started in 2021, is one of 47 with no phase, and was the 120th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →14 of the 157 studies in Multiple Sclerosis with a site in Belgium are open now. Recruiting first, the newest first:
Daphne Kos · Sites in Belgium, Denmark
Ages 18+
Sanofi · Sites in Belgium, United States, Brazil and 4 more countries
Ages 18–60
Hasselt University · Sites in Belgium
Ages 18–65 · Healthy volunteers
Novartis Pharmaceuticals · Sites in Belgium, United States, Argentina and 33 more countries
Ages 18–65
Hasselt University · Sites in Belgium, Italy, Spain
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
157 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 19 · Phase 3 53 · Phase 4 11
First in 1999; this study’s year is marked. 8 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 163 across the 132 interventional studies, 100 across the 25 observational. Of the 122 that completed or were terminated, 55 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
92 of 157 have an industry lead sponsor. The 10 most frequent:
Laurent Servais is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Laurent Servais has 1 study filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
8 of the studies in Multiple Sclerosis with a site in Belgium that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT07325292Phase 3SanofiNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | 2027-07-15 |
| NCT07316764University of LiegeEccentric Cycling in Multiple Sclerosis Rehabilitation | 2026-12-30 |
| NCT05893225University Hospital, AntwerpMetformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration | 2027-02-28 |
| NCT05704361Hoffmann-La RocheA Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis | 2027-07-08 |
Add all 8 to your calendar (.ics) → With an account.
Among the 157 studies in Multiple Sclerosis with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
ActiSEP is a multicentric academic study. Ambulant patients with multiple sclerosis may be included on a voluntary basis. We plan to include a group of approximately 20 patients with MS.
This study include a unique evaluation in the laboratory of analysis of human movement. A set of tasks will be performed by patients wearing of two magneto-inertial sensors.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ambulant patients with multiple sclerosis
Device: Actimyo° · Device: IMU
Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
IMU is a portable system of miniaturized inertial sensors for objective, instrumental, ambulatory, and validated analysis of normal and pathological human gait. Each miniaturized inertial sensor (2 cm × 0.7 cm × 0.5 cm) includes a triaxial accelerometer and a triaxial gyroscope. These four inertial sensors are connected to a box by wires and are numbered 1 to 4. They must be attached - using adhesive tapes - on the participant's shoes.
95th centile of stride velocity
95th centile of stride velocity obtained with magneto-inertial sensors and a motion capture device (meter/second).
Time frame: One day
50th centile of stride velocity
50th centile of stride velocity obtained with magneto-inertial sensors and a motion capture device (meter/second).
Time frame: One day
95th centile of stride length
95th centile of stride length obtained with magneto-inertial sensors and a motion capture device (meter).
Time frame: One day
50th centile of stride length
50th centile of stride length obtained with magneto-inertial sensors and a motion capture device (meter).
Time frame: One day
Stance phase time
Stance time over full stride time for each foot obtained with magneto-inertial sensors and a motion capture device (percentage).
Time frame: One day
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2021 to primary completion in Sep 2021, 7 months.
Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's 7 months is below that.
Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Laurent Servais